Sanofi Expands Immunology Prospects, Acquiring Novel Bispecific Drug in $600M Deal
Sanofi is building on its immunology ambitions by acquiring an early clinical Dren Bio drug candidate that offers a potential first-in-class approach to autoimmune disorders such as lupus. It’s the latest acquisition in what has become an active space for dealmaking. The post Sanofi Expands Immunology Prospects, Acquiring Novel Bispecific Drug in $600M Deal appeared first on MedCity News.
Sanofi is building on its immunology ambitions by acquiring an early clinical Dren Bio drug candidate that offers a potential first-in-class approach to autoimmune disorders such as lupus. It’s the latest acquisition in what has become an active space for dealmaking.
The post Sanofi Expands Immunology Prospects, Acquiring Novel Bispecific Drug in $600M Deal appeared first on MedCity News.
